Skip to main content
. Author manuscript; available in PMC: 2018 Apr 25.
Published in final edited form as: ACS Nano. 2018 Apr 2;12(4):3658–3670. doi: 10.1021/acsnano.8b00797

Figure 7.

Figure 7

In vivo validation of therapeutic efficacy. (A) Schedule of the treatments. (B) Paralysis-free survival and (C) body weight of mice after the treatments (n = 4–5). (D) Flow cytometry analysis of residual Raji 4RH cells (human CD10+CD19+) in the bone marrow (BM). BM cells were isolated from the femur of mice at end point (onset of paralysis), and Raji 4RH cells were dual stained with PE-labeled mouse antihuman CD10 and APC-labeled mouse antihuman CD19 antibodies. Three mice from 2P-GEM → DFMT treatment group that did not undergo paralysis were also sacrificed for antilymphoma efficacy comparison at days 27, 43, and 43, respectively.